+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Chronic kidney disease and kidney failure most often develop in adults, especially those with diabetes or high blood pressure. Over time, the kidneys lose their ability to filter waste and balance minerals, which can lead to serious complications. Re...

Search Bar & Filters

Found 224 Actively Recruiting clinical trials

P

Actively Recruiting

This clinical trial studies patients with hyperphosphatemia who are undergoing peritoneal dialysis due to chronic kidney disease. It is an open-label, single-arm Phase 3 study sponsored by Taisho Pharmaceutical Co., Ltd., aiming to evaluate the effect of TS-172 on lowering serum phosphorus levels. The trial focuses on patients who have been on peritoneal dialysis for at least 12 weeks and are currently receiving phosphate binders with stable dosing. Participants receive oral TS-172 at doses ranging from 20 to 60 mg per day. The study runs through multiple visits starting from a screening period to treatment and evaluation up to Week 16. The primary measurement is the rate of achieving the target serum phosphorus level at Week 8. Secondary measures include changes in serum phosphorus, corrected serum calcium, and serum calcium-phosphorus product over 16 weeks. During the study, participants undergo regular blood tests to monitor phosphorus and calcium levels. The researchers track adherence to medication and evaluate biochemical changes. The study includes safety monitoring and follow-up assessments throughout the 16-week observation period. Participants involvement spans from initial screening through treatment and evaluation phases, concluding with the primary outcome assessment at Week 8 and extended follow-up to Week 16.

Age: 18Years +All GendersPhase 3
1 location
P

Actively Recruiting

Researchers are conducting a prospective, multicenter observational study focused on kidney transplant recipients aged 18 and older. The study aims to collect blood samples and clinical data to help develop a non-invasive test that detects donor-derived cell-free DNA dd-cfDNA in these patients. This test is intended to evaluate the status of the transplanted kidney. Participants will provide whole blood samples at the time of an indication biopsy, which is a biopsy performed when there is a clinical reason to do so. Retrospective, de-identified leftover genetic material samples from the original kidney donors will also be collected for comparison. No treatment or intervention is administered as part of this study. During the study, researchers will analyze the collected blood samples and data to detect dd-cfDNA over an 18-month period. Participants will be monitored through their clinical biopsies and data collection. The study duration extends until March 2028, allowing for comprehensive evaluation of the tests ability to assess renal transplant status over time.

Age: 18Years +All Genders
6 locations
I

Actively Recruiting

Researchers are evaluating a new combination of evidence-based interventions EBIs aimed at improving diagnostic safety and efficiency in primary care for patients with anemia and decreased glomerular filtration rate. The study is designed as a stepped wedge cluster randomized control trial to measure how these interventions affect patient safety and healthcare efficiency, while also assessing factors influencing their implementation such as acceptability, cost, and sustainability. The study compares an enhanced diagnostic team approach to usual care. The enhanced approach includes automated detection and tracking of abnormal test results, expanding the primary care team to include clinical pharmacists to guide anemia evaluation, and engaging patients through nurse navigators to increase their activation in the diagnostic process. The study involves several clinic groups that receive the intervention at different times, ranging from 12 to 24 months, with some initial control periods. Participants will have their diagnostic accuracy for causes of low hemoglobin and decreased glomerular filtration rate assessed within six months. Researchers will track time to diagnosis, appropriate test usage, treatment costs, and primary care physicians views on the interventions acceptability and feasibility. The study also monitors how well the diagnostic process steps are followed, the interventions reach among patients, and sustainability in clinics over 2.5 years. Patient activation and clinic-level facilitators and barriers are evaluated through surveys and measures during the study period.

Age: 18Years +All GendersPhase Not Applicable
1 location
S

Actively Recruiting

Healthy Volunteer

Researchers are studying the effects of Azvudine, a nucleoside reverse transcriptase inhibitor and broad-spectrum RNA virus inhibitor, on people with mild to moderate renal insufficiency and healthy individuals. This Phase 1 trial aims to understand how different levels of kidney function affect the drugs behavior in the body, its safety, and how well it is tolerated. The study is sponsored by Henan Genuine Biotech Co., Ltd. and involves adult participants aged 18 to 70 years old. Participants receive a single oral dose of 3 mg Azvudine tablets three tablets taken on an empty stomach on the first day of the study. The trial includes three groups those with mildly decreased kidney function, those with moderately decreased kidney function, and healthy volunteers matched by age, weight, and gender. The study uses an open-label, non-randomized, parallel design to monitor how the drug is processed in these groups. During the trial, blood and urine samples are collected up to 48 and 72 hours after dosing, respectively, to measure drug levels and other pharmacokinetic parameters. Safety exams and monitoring for any adverse effects occur from enrollment until day 4. Researchers evaluate outcomes such as maximum drug concentration, area under the concentration-time curve, and elimination half-life to understand the drugs behavior in participants with varying kidney function. The total study period includes screening, drug administration, and follow-up assessments.

Age: 18Years - 70YearsAll GendersPhase 1
1 location
E

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.

Age: 18Years - 99YearsAll GendersPhase 3
478 locations
U

Actively Recruiting

Researchers are evaluating whether using a digital smartphone application can help adults with chronic kidney disease CKD better follow the 2024 Kidney Disease Improving Global Outcomes KDIGO guidelines. The study focuses especially on young adults transitioning from pediatric to adult nephrology care, who face higher risks and challenges during this vulnerable period. The research aims to improve treatment adherence and health outcomes by addressing gaps in current care and guideline implementation. Participants will use a modified version of the St. Jamess Hospital Renal App, which has been adapted to align with the KDIGO 2024 guidelines. The app provides tailored recommendations, reminders, educational materials, and collects patient-reported outcomes. The study uses a randomized stepped wedge design where patients receive first exposure and later continued use of the app. The intervention supports healthcare providers by highlighting opportunities for evidence-based therapies and helps patients manage their care digitally. During the study, participants will be monitored for changes in adherence to KDIGO guidelines over 18 months. Assessments will include patient engagement, clinical data integration via electronic health records, and patient-reported measures. The app also supports appointment management and medication reminders, aiming to enhance self-management and slow CKD progression. The research includes diverse patient subgroups and considers cultural and linguistic needs to promote equitable care.

Age: 16Years - 30YearsAll GendersPhase Not Applicable
2 locations
A

Actively Recruiting

Researchers are evaluating AP301, a novel iron-based phosphate binder, in patients with chronic kidney disease who are receiving maintenance dialysis and have elevated blood phosphate levels. This phase 3, randomized, double-blind study aims to determine whether AP301 lowers blood phosphate and how it affects serum calcium, calcium times phosphate, and intact parathyroid hormone levels. The trial also assesses any discomfort or medical problems during treatment and its impact on quality of life in Chinese patients. Participants will first stop all phosphate-lowering medications. They will then take either AP301 or a low-dose comparator considered ineffective three times daily for 8 weeks. Following this, all participants receive AP301 three times daily for 24 weeks, with dose adjustments based on blood phosphate levels and physician judgment. Finally, participants will take either AP301 or the comparator three times daily for 3 weeks. Additional treatments may be given if blood phosphate levels become too high or low. During the study, participants will undergo regular assessments including blood tests to monitor serum phosphate, calcium, and parathyroid hormone levels. Electrocardiogram tests will measure changes in QT intervals. Safety is monitored by tracking adverse events throughout the trial, which lasts up to 37 weeks. The primary outcome is the change in serum phosphate concentration from baseline to the end of week 8, with ongoing evaluations over the entire study period.

Age: 12Years +All GendersPhase 3
42 locations
R

Actively Recruiting

Researchers are evaluating clazakizumab, a drug administered by subcutaneous injection, to study its effect on reducing high-sensitivity C-reactive protein hsCRP, a marker of inflammation, in adults with elevated hsCRP and increased risk for cardiovascular events. This phase 2b, randomized, double-blind, placebo-controlled study focuses on adults with established atherosclerotic cardiovascular disease or other risk factors such as obesity, type 2 diabetes, hypertension, or chronic kidney disease. The study aims to understand how clazakizumab compares to placebo in lowering inflammation related to cardiovascular risk. Participants will receive one of several doses of clazakizumab or a placebo via subcutaneous injection. The treatment period involves dosing and monitoring up to 32 weeks, with the primary outcome measured at 12 weeks and additional assessments at 24 weeks. The study includes a double-blind design where neither participants nor researchers know who receives the active drug or placebo. Pharmacokinetics of clazakizumab will also be evaluated during the trial. Throughout the approximately 9-month participation, participants will undergo blood tests to measure hsCRP levels at baseline and multiple follow-up points, including week 12 and week 24. Researchers will assess the percent change in hsCRP to evaluate inflammation changes. Safety and drug concentration will be monitored regularly. Participants will have scheduled visits for study drug administration and assessments, ensuring careful observation during the study period.

Age: 18Years +All GendersPhase 2
46 locations
S

Actively Recruiting

Researchers are evaluating the safety, tolerability, pharmacokinetics, and efficacy of AP1189 in patients with idiopathic membranous nephropathy iMN who have severe proteinuria. This exploratory, randomized, double-blind, placebo-controlled study focuses on patients already receiving ACE inhibitor or angiotensin II receptor blocker treatment, aiming to understand how AP1189 affects these patients over a 12-week period. Participants will be randomly assigned in a 21 ratio to receive either 100 mg of AP1189 or a matching placebo daily for 12 weeks, alongside their ongoing treatments. The study is conducted at multiple centers and maintains a triple-blind design to ensure unbiased results. The AP1189 and placebo are administered as tablets taken once each day during the treatment period. During the study, participants will undergo regular monitoring including assessments of adverse events, blood tests for liver enzymes and bilirubin, and measurements of protein levels in urine over 24 hours. Researchers will also track albumin levels in urine. These evaluations occur up to week 12, covering safety and treatment effects. The studys total duration includes screening, 12 weeks of treatment, and follow-up to capture all relevant data on patient health and response to the investigational drug.

Age: 18Years - 85YearsAll GendersPhase 2
1 location
S

Actively Recruiting

Researchers are evaluating the safety, tolerability, and effectiveness of AP306 at fixed doses in adults with hyperphosphatemia who are undergoing maintenance hemodialysis. Hyperphosphatemia is a common complication in advanced chronic kidney disease and is linked to increased risks of cardiovascular problems, fractures, and mortality, especially in dialysis patients. This randomized, double-blind, placebo-controlled study aims to better understand how well AP306 works to lower phosphate levels in this population. Participants will receive AP306 in varying doses, taken orally either twice or three times daily, or a placebo over an 8-week treatment period. The study includes several cohorts with different fixed dose regimens of AP306 or placebo. Treatment is given daily, and the study compares the ability of AP306 to lower serum phosphate compared to placebo. During the study, participants will be regularly assessed for phosphate levels and other safety measures. Researchers will monitor serum phosphate reduction, the proportion of participants reaching target phosphate levels, and time to response while ensuring tolerability and safety. The study is expected to last approximately 8 weeks of treatment with ongoing monitoring to evaluate the drugs effects and participant well-being.

Age: 18Years +All GendersPhase 2
31 locations

1-10 of 224

1

Frequently Asked Questions